Harbor Capital Advisors Inc. Purchases 380,790 Shares of Evolent Health, Inc. (NYSE:EVH)

Harbor Capital Advisors Inc. increased its position in Evolent Health, Inc. (NYSE:EVH) by 90.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 803,211 shares of the technology company’s stock after purchasing an additional 380,790 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in Evolent Health were worth $9,036,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Quarry LP purchased a new position in Evolent Health during the second quarter valued at $32,000. Covestor Ltd lifted its position in Evolent Health by 138.1% during the 3rd quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock valued at $40,000 after acquiring an additional 826 shares during the period. GAMMA Investing LLC boosted its stake in Evolent Health by 5,365.5% during the third quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock worth $45,000 after acquiring an additional 1,556 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in Evolent Health in the second quarter worth about $61,000. Finally, Quest Partners LLC purchased a new position in shares of Evolent Health during the second quarter valued at approximately $87,000.

Evolent Health Stock Performance

Shares of NYSE:EVH traded down $0.42 during trading on Friday, hitting $12.18. The company’s stock had a trading volume of 583,130 shares, compared to its average volume of 1,314,679. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of -13.38 and a beta of 1.45. The company has a 50-day moving average of $13.13 and a 200-day moving average of $21.09. Evolent Health, Inc. has a 12 month low of $10.53 and a 12 month high of $35.00.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on EVH shares. Oppenheimer cut their target price on Evolent Health from $34.00 to $28.00 and set an “outperform” rating on the stock in a research note on Monday, November 18th. BTIG Research reduced their price target on shares of Evolent Health from $36.00 to $29.00 and set a “buy” rating for the company in a research report on Tuesday, December 3rd. Needham & Company LLC assumed coverage on shares of Evolent Health in a report on Friday. They issued a “buy” rating and a $15.00 price objective for the company. KeyCorp initiated coverage on Evolent Health in a research note on Friday, October 11th. They set an “overweight” rating and a $35.00 target price on the stock. Finally, Barclays lowered their price target on Evolent Health from $39.00 to $19.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. One analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $24.17.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.